Zeitschrift fur Rheumatologie最新文献

[This is how I treat Castleman's disease].

IF 1 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2025-07-31 DOI: 10.1007/s00393-025-01690-4

Christian Hoffmann

引用次数: 0

[Anti-CD19 treatment: the new gold standard for IgG4-related diseases].

IF 1 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2025-07-31 DOI: 10.1007/s00393-025-01682-4

Martin Krusche

{"title":"[Anti-CD19 treatment: the new gold standard for IgG4-related diseases].","authors":"Martin Krusche","doi":"10.1007/s00393-025-01682-4","DOIUrl":"https://doi.org/10.1007/s00393-025-01682-4","url":null,"abstract":"Immunoglobulin G4-related disease (IgG4-RD) is an immune-mediated, inflammatory, fibrosing multiorgan disease. The B cells and plasma cells play a central role in the pathophysiology, which makes B cell-targeted treatment particularly interesting for the disease. Although glucocorticoids still represent the first line treatment, recurrence under dose reduction is frequent. Immunosuppressants, such as methotrexate, azathioprine, mycophenolate mofetil or rituximab (anti-CD20) are used but larger studies on proof of benefits are lacking so that no approved treatment options for the disease currently exist. Using CD19 as the therapeutic target addresses a broad spectrum of B cell differentiation including plasmablasts. The multicenter randomized placebo-controlled phase 3 study MITIGATE (n = 135) first investigated the anti-CD19 antibody inebilizumab in active IgG4-RD. The treatment significantly reduced the risk of recurrence (10% vs. 60% under placebo), the annual exacerbation rate and the necessity for renewed administration of glucocorticoids. Additionally, under inebilizumab there was a median reduction of the IgG4 serum level of around 50% and a persisting depletion of B cells during the study period of 52 weeks. Severe undesired events occurred more frequently with inebilizumab, particularly infections and lymphopenia but without treatment-associated cases of death. Following approval of inebilizumab by the U.S. Food and Drug Administration (FDA) for IgG4-RD in 2025, approval in Europe is also soon to be expected. The anti-CD19 targeted treatment with inebilizumab could therefore become the new approved gold standard; however, long-term data on remission maintenance and health economic issues, especially in comparison to off-label treatment such as rituximab remain the subject of further research. New approaches, such as CD19 chimeric antigen receptor (CAR) T cell treatment or bispecific T cell engagers could furthermore open up future treatment options.","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Disease-modifying antirheumatic drug and malignant diseases : Carol Nachman Symposium 2025]. [改善疾病的抗风湿药物和恶性疾病：Carol Nachman Symposium 2025]。

IF 1 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2025-07-30 DOI: 10.1007/s00393-025-01698-w

Marc Schmalzing

引用次数: 0

[Management of pulmonary and cardiovascular comorbidities in rheumatological diseases]. [风湿病中肺部和心血管合并症的管理]。

IF 1 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2025-07-30 DOI: 10.1007/s00393-025-01679-z

P Xanthouli, A Schatz, R Bergner, K Triantafyllias

引用次数: 0

[When is there an indication for treatment of isolated leukopenia in SLE and how should it be treated?] SLE孤立性白细胞减少症的治疗指征是什么时候？应该如何治疗？］

IF 1 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2025-07-29 DOI: 10.1007/s00393-025-01683-3

Matthias Schneider

引用次数: 0

[This is how I diagnose Castleman's disease]. （这就是我诊断卡斯尔曼氏病的方法）。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2025-07-23 DOI: 10.1007/s00393-025-01681-5

Christian Hoffmann

引用次数: 0

[Immunoadsorption in rheumatic autoimmune diseases: an alternative treatment option : Retrospective insights on the clinical application from the Rhineland-Palatinate Rheumatology Center]. [免疫吸附治疗风湿性自身免疫性疾病：另一种治疗选择：莱茵兰-普法尔茨风湿病中心临床应用的回顾性见解]。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2025-07-22 DOI: 10.1007/s00393-025-01677-1

Konstantinos Triantafyllias, Ann-Kathrin Dapper, Andreas Schwarting

{"title":"[Immunoadsorption in rheumatic autoimmune diseases: an alternative treatment option : Retrospective insights on the clinical application from the Rhineland-Palatinate Rheumatology Center].","authors":"Konstantinos Triantafyllias, Ann-Kathrin Dapper, Andreas Schwarting","doi":"10.1007/s00393-025-01677-1","DOIUrl":"https://doi.org/10.1007/s00393-025-01677-1","url":null,"abstract":"Background: Systemic inflammatory rheumatic diseases are frequently linked to significant morbidity and, in some cases, can lead to severe, chronic disease courses. Early and effective treatment strategies are required to prevent irreversible damage. Drug-based immunosuppression is not possible for all patients. In such cases the use of alternative treatment, such as immunoadsorption (IA) is of particular interest. Despite positive clinical experiences, the data on the use of IA in rheumatic diseases are limited.Objective: The aim was to analyze the application, efficacy and safety of IA under routine conditions.Material and methods: In this retrospective study immunoadsorption (IA) treatment was performed 373 times in 31 patients with various rheumatic diseases.Results and discussion: The results show that IA was predominantly used in combination with other medicinal procedures, often as a bridging therapy or as a last resort in complex cases. The treatment showed a good safety profile: 25% of patients experienced mainly mild side effects such as a short-term drops in blood pressure. The use of IA led to a significant reduction in immunoglobulin levels. A positive clinical therapeutic effect was observed in 48% of the cases. Shorter intervals between treatments were associated with a better clinical response (p = 0.004). A correlation between a positive therapeutic effect and the concomitant glucocorticoid therapy could not be established (p = 0.611), which could potentially indicate an independent effect of IA.Conclusion: The use of IA can be a valuable addition to individualized treatment approaches and should be further evaluated in future studies.","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Upadacitinib demonstrates significant efficacy in giant cell arteritis: results from the SELECT-GCA study]. 【Upadacitinib对巨细胞动脉炎有显著疗效：来自SELECT-GCA研究的结果】。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2025-07-22 DOI: 10.1007/s00393-025-01684-2

Valentin S Schäfer

引用次数: 0

[Adult chronic nonbacterial osteitis : A uniform approach to a rare disease-Reported according to the consensus recommendations of an international expert committee 2025]. [成人慢性非细菌性骨炎：一种罕见疾病的统一方法-根据2025年国际专家委员会的共识建议报道]。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2025-07-21 DOI: 10.1007/s00393-025-01688-y

Philipp Klemm, Pascal van Wijnen, Gunter Assmann

{"title":"[Adult chronic nonbacterial osteitis : A uniform approach to a rare disease-Reported according to the consensus recommendations of an international expert committee 2025].","authors":"Philipp Klemm, Pascal van Wijnen, Gunter Assmann","doi":"10.1007/s00393-025-01688-y","DOIUrl":"https://doi.org/10.1007/s00393-025-01688-y","url":null,"abstract":"Adult chronic nonbacterial osteitis (CNO) is a rare autoinflammatory bone disease formerly described under heterogeneous terms, such as SAPHO (acronym for synovitis, acne, pustulosis, hyperostosis and osteitis) or sternocostoclavicular hyperostosis (SCCH). New international consensus recommendations now define adult CNO as a distinct nosological entity with osteitis as the obligatory hallmark. The disease typically presents as monofocal inflammation of the anterior chest wall; cutaneous manifestations are not obligatory. Overlaps with axial spondylarthritis (axSpA) or psoriatic arthritis (PsA) are recognized but uncommon (< 30% of cases). The diagnostics follow a structured algorithm involving clinical assessment, targeted laboratory diagnostics (including bone metabolism markers) and magnetic resonance imaging (MRI)-based imaging. Treatment decisions are based on the combined presence of clinical symptoms and radiological activity. A stepwise approach is recommended, starting with nonsteroidal anti-inflammatory drugs (NSAID), followed by intravenous bisphosphonates or tumor necrosis factor (TNF) alpha inhibitors in cases of insufficient response. Treatment monitoring should be carried out every 12 weeks. In stable remission, tapering or withdrawal can be considered. All specific therapies are performed off-label and require formal reimbursement approval. The management should be rheumatologically led and interdisciplinary. Lifestyle modifications, such as smoking cessation, physical activity and dental care during bisphosphonate therapy, are integral components. The new recommendations enable a clinically applicable, standardized management of this insufficiently defined disease.","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Diagnostics and treatment of gout : Short version of the German S3 guideline]. 【痛风的诊断和治疗：德国S3指南的简短版本】。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2025-07-21 DOI: 10.1007/s00393-025-01633-z

Anne-Kathrin Tausche, Thomas Schneidereit, Hendrik Napierala, Monika Reuß-Borst, Philipp Klemm, Jürgen Clausen, Harriet Morf, Julia Truthmann, Ilja Karl, Bettina Engel, Gernot Keyßer, Ulf Müller-Ladner, Ralph Kettritz, Jan Kielstein, Marcus Makowski, Christian Booz, Hans-Dieter Carl, Ralph Gaulke, Olaf Adam, Andreas Michalsen, Michaela Fritsch, Rieke Alten, Bernhard Manger, Klaus Krüger, Wolfgang A Schmidt, Andreas Schwarting, Jürgen Braun, Uta Kiltz

引用次数: 0